Drug intelligence / Profile preview

JPX-1185

Development stage: Preclinical
Lead developer: Centessa Pharmaceuticals
Modality: Small Molecules

Overview

JPX-1185 is a preclinical small-molecule targeted protein degrader designed to simultaneously target the STAT3 and STAT5 transcription factors, key oncogenic signaling nodes in a range of hematologic malignancies and solid tumors. Developed by Janpix Holdings, the molecule is intended to exploit proteolysis-targeting mechanisms to reduce STAT3/STAT5 protein levels and thereby inhibit downstream survival and proliferation pathways in cancer cells. It is being explored for neoplastic and hemic/lymphatic indications, but has not yet entered clinical trials or achieved regulatory approval.

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)STAT5A (STAT5)

Beyond the preview

Go deeper on JPX-1185.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JPX-1185.

Explore the full profile